Recent Developments in the Healthcare Sector: Special Research on Neurocrine Biosciences, Novavax, NPS Pharma, Osiris Therapeutics, and OXiGENE
NEW YORK, February 18, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Neurocrine Biosciences (NYSE: NBIX), Novavax (NYSE: NVAX), NPS Pharma (NYSEMKT: NPSP), Osiris Therapeutics (NYSEMKT: OSIR), and OXiGENE (NYSE: OXGN). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
NBIX Research Report: ( http://get.analystsreview.com/pdf/?c=Neurocrine%20Biosciences&d=18-Feb-2015&s=NBIX ),
NVAX Research Report: ( http://get.analystsreview.com/pdf/?c=Novavax&d=18-Feb-2015&s=NVAX ),
NPSP Research Report: ( http://get.analystsreview.com/pdf/?c=NPS%20Pharma&d=18-Feb-2015&s=NPSP ),
OSIR Research Report: ( http://get.analystsreview.com/pdf/?c=Osiris%20Therapeutics&d=18-Feb-2015&s=OSIR ),
OXGN Research Report: ( http://get.analystsreview.com/pdf/?c=OXiGENE&d=18-Feb-2015&s=OXGN ).
============
--
Analyst Update: Quarterly Results, Appointments, FDA Approvals, Upcoming Earnings, and Patent Issuance
Reviewed by: Rohit Tuli, CFA®
The US market ended Tuesday's session with modest gains on growing optimism among investors that Greece will seek an extension to its rescue deal on Wednesday, following an unsuccessful talk on Monday. Although three US key benchmark indices started the day in the negative zone, stocks gained momentum in the afternoon hours as investors kept an eye on talks between Greece and its Eurozone creditors, helping S&P 500 and Dow Jones Industrial Average to score fresh records at day end. The S&P 500 gained 3.35 points or 0.16% to end at 2,100.34, another new record closing high. The Dow edged up 28.26 points or 0.16% to 18,047.58, which is a new 2015 record, while the NASDAQ Composite inched up 5.43 points or 0.11% to 4,899.27. During the day, US traders also largely shrugged off report from the National Association of Home Builders that showed an unexpected deterioration in homebuilder confidence. Meanwhile, the European market ended on mixed note on Tuesday on reports of Greece's resistance towards an extension of the current bailout program, while Eurozone ministers refused to loosen their terms.
Neurocrine Biosciences, Inc. (Neurocrine Biosciences) recently announced its Q4 and full-year 2014 results. Losses widened both for the quarter and for the year, primarily due to increased research and development expenses in connection with the Company's expanding clinical stage pipeline and higher share-based compensation expense.
Novavax, Inc. (Novavax) announced the appointment of Jill Hoyt as Vice President, Human Resources & Administration. Ms. Hoyt joined Novavax in February 2008 as Executive Director, Human Resources & Administration and has been key in the successful growth of the Company.
NPS Pharmaceuticals, Inc. (NPS Pharma) announced that the U.S. Food and Drug Administration (FDA) has approved Natpara® (parathyroid hormone) as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism-a rare endocrine disorder featuring insufficient levels of parathyroid hormone (PTH).
Osiris Therapeutics, Inc. (Osiris Therapeutics) has scheduled to report its Q4 and full-year 2014 financial results on Thursday, March 5, 2015, before market opens. Following the release, Lode Debrabandere, Ph.D., President and CEO, and Philip R. Jacoby, Jr., CFO, will provide a Company update and discuss results via a webcast and conference call at 9:00 a.m. ET., that same day.
The European Patent Office granted a patent to OXiGENE, Inc. (OXiGENE) related to its current clinical product candidate, OXi4503, for treating non-solid myeloid neoplasm, including acute myeloid leukemia (AML).
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article